RXRX · Recursion Pharmaceuticals Inc
United States · RS rating 52 · As of 2026-11-03
| Price | 3.68 USD |
|---|---|
| 1-day change | -3.9% |
| RS rating (overall / 1M / 3M / 12M) | 52 / 18 / 87 / 29 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 36 / 14 / 54 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +41.7% |
| Sales growth Q/Q | +609.4% |
| Distance from 52-week high | +32.4% |
| Market cap (USD) | $1.8B |